503 related articles for article (PubMed ID: 22560921)
61. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
[TBL] [Abstract][Full Text] [Related]
62. A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104.
Govindan R; Wang X; Baggstrom MQ; Burdette-Radoux S; Hodgson L; Vokes EE; Green MR;
J Thorac Oncol; 2009 Feb; 4(2):220-6. PubMed ID: 19179900
[TBL] [Abstract][Full Text] [Related]
63. A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Laack E; Thöm I; Krüll A; Engel-Riedel W; Müller T; Meissner C; Dürk H; Fischer J; Gütz S; Kortsik C; Elbers M; Schuch G; Andritzky B; Görn M; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C
Lung Cancer; 2007 Aug; 57(2):181-6. PubMed ID: 17442447
[TBL] [Abstract][Full Text] [Related]
64. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer.
Wakuda K; Kenmotsu H; Naito T; Akamatsu H; Ono A; Shukuya T; Nakamura Y; Tsuya A; Murakami H; Takahashi T; Endo M; Nakajima T; Yamamoto N
Am J Clin Oncol; 2015 Feb; 38(1):28-32. PubMed ID: 23388567
[TBL] [Abstract][Full Text] [Related]
65. Carboplatin plus etoposide for extensive stage small-cell lung cancer: an experience with AUC 6 doses of carboplatin.
Yilmaz U; Polat G; Anar C; Halilcolar H
Indian J Cancer; 2011; 48(4):454-9. PubMed ID: 22293260
[TBL] [Abstract][Full Text] [Related]
66. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
[TBL] [Abstract][Full Text] [Related]
67. A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.
Spigel DR; Hainsworth JD; Gandhi JG; Gian VG; Peyton JD; West-Osterfield K; Clark BL; Vazquez ER; Jones SF; Burris HA; Greco FA
J Thorac Oncol; 2010 Jun; 5(6):862-6. PubMed ID: 20521352
[TBL] [Abstract][Full Text] [Related]
68. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.
Hermes A; Bergman B; Bremnes R; Ek L; Fluge S; Sederholm C; Sundstrøm S; Thaning L; Vilsvik J; Aasebø U; Sörenson S
J Clin Oncol; 2008 Sep; 26(26):4261-7. PubMed ID: 18779613
[TBL] [Abstract][Full Text] [Related]
69. A phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small cell lung cancer.
Fukuda M; Nakamura Y; Kasai T; Nagashima S; Nakatomi K; Doi S; Nakano H; Takatani H; Fukuda M; Kinoshita A; Soda H; Tsukamoto K; Oka M; Kohno S;
J Thorac Oncol; 2009 Jun; 4(6):741-5. PubMed ID: 19404211
[TBL] [Abstract][Full Text] [Related]
70. Randomized phase II trial of weekly dose-intensive chemotherapy or amrubicin plus cisplatin chemotherapy following induction chemoradiotherapy for limited-disease small cell lung cancer (JCOG1011).
Sekine I; Harada H; Yamamoto N; Wakabayashi M; Murakami H; Goto K; Nogami N; Seto T; Oshita F; Okamoto H; Tanaka H; Tamura T; Ishikura S; Ohe Y
Lung Cancer; 2017 Jun; 108():232-237. PubMed ID: 28625642
[TBL] [Abstract][Full Text] [Related]
71. Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
Ishimoto O; Sugawara S; Inoue A; Maemondo M; Nukiwa T
Respir Investig; 2015 Jul; 53(4):156-60. PubMed ID: 26100175
[TBL] [Abstract][Full Text] [Related]
72. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).
Pandya KJ; Dahlberg S; Hidalgo M; Cohen RB; Lee MW; Schiller JH; Johnson DH;
J Thorac Oncol; 2007 Nov; 2(11):1036-41. PubMed ID: 17975496
[TBL] [Abstract][Full Text] [Related]
73. Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401.
Takayama K; Inoue K; Tokunaga S; Matsumoto T; Oshima T; Kawasaki M; Imanaga T; Kuba M; Takeshita M; Harada T; Shioyama Y; Nakanishi Y
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1353-9. PubMed ID: 24166107
[TBL] [Abstract][Full Text] [Related]
74. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
[TBL] [Abstract][Full Text] [Related]
75. [Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].
Yashiki C; Hirose T; Okuda K; Yamaoka T; Ohnishi T; Adachi M; Nakamura A
Gan To Kagaku Ryoho; 2009 Nov; 36(11):1839-43. PubMed ID: 19920385
[TBL] [Abstract][Full Text] [Related]
76. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
77. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
78. A phase I study of amrubicin and fixed dose of irinotecan (CPT-11) in relapsed small cell lung cancer: Japan multinational trial organization LC0303.
Kawahara M; Kubo A; Komuta K; Fujita Y; Sasaki Y; Fukushima M; Daimon T; Furuse K; Mishima M; Mio T
J Thorac Oncol; 2012 Dec; 7(12):1845-1849. PubMed ID: 22139390
[TBL] [Abstract][Full Text] [Related]
79. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
[TBL] [Abstract][Full Text] [Related]
80. Phase 2 trial of pemetrexed disodium and carboplatin in previously untreated extensive-stage small cell lung cancer, N0423.
Chee CE; Jett JR; Bernath AM; Foster NR; Nelson GD; Molina J; Nikcevich DA; Steen PD; Flynn PJ; Rowland KM
Cancer; 2010 May; 116(10):2382-9. PubMed ID: 20209614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]